• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

FIPNET a proven success

Anonymous

Guest
The experts are predicting our stock will hit $92. That's way up from the $28 it was 6+ years ago. Time to stop bad mouthing the leadership and admit that John's leadership and strategy have lead us through the storm. FIPNET is a success and so it Lilly. The proof is evident. If you don't like it here, then you don't belong on this success team. Thanks for all your hard work John. You've been worth every penny.